Low limit of detection for rare antigen-specific T cells translates to clinical sensitivity and specificity.
The company’s key, proprietary intellectual property is the Novoleukin test system, a “whole blood antigen-stimulated cytokine release assay” which is substantially more sensitive than conventional fresh PBMC-based ELISpot assay (e.g. for detection of gluten-reactive CD4+ T cells in celiac disease).
Novoviah provides test kits designed for your therapeutic, allowing immune monitoring at community clinical sites during trials.
Your headphones should always look amazing! Pick your preferred color.
Only 4 ml blood sample is required for each test condition; for example, in celiac disease studies this can ease the burden on patients and sites by reducing the need for invasive or unpleasant procedures such as endoscopic biopsies or “gluten food challenge”.
The protocol for blood collection and processing is simple and reproducible, to enable easy rollout across multiple sites.
The Novoleukin Test System comprises three elements:
Novoviah is dedicated to pioneering sensitive clinical tests for antigen-specific T cells, supporting clinical trials for drug developers and researchers. Established in 2020, Novoviah specialised in developing a cutting-edge testing platform for clinical trials and aspires to expand its usage into healthcare settings in the future. With a focus on enhancing pharmaceutical programs, Novoviah is committed to developing customised and highly precise blood tests for a variety of medical conditions associated with antigen-specific T cells.
Novoviah Pharmaceuticals Pty Ltd | Novoviah, NovoGluten, NovoLeukin and NovoFind are all registered trademarks. | Website maintained & hosted by Web Set Go